Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC ; volume:24 ; number:1 ; day:24 ; month:10 ; year:2024 ; pages:1-11 ; date:12.2024
BMC cancer ; 24, Heft 1 (24.10.2024), 1-11, 12.2024
- Urheber
-
Santoro, Armando
Pilar, Garrido
Tan, Daniel S.W
Zugazagoitia, Jon
Shepherd, Frances A.
Bearz, Alessandra
Barlesi, Fabrice
Kim, Tae Min
Overbeck, Tobias R.
Felip, Enriqueta
Cai, Can
Eddy, Simantini
McCulloch, Tracey
Schaefer, Eric S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12841-2
- URN
-
urn:nbn:de:101:1-2502072116245.450246999958
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Santoro, Armando
- Pilar, Garrido
- Tan, Daniel S.W
- Zugazagoitia, Jon
- Shepherd, Frances A.
- Bearz, Alessandra
- Barlesi, Fabrice
- Kim, Tae Min
- Overbeck, Tobias R.
- Felip, Enriqueta
- Cai, Can
- Eddy, Simantini
- McCulloch, Tracey
- Schaefer, Eric S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets
C–H Arylation with Platinum
Constraints on the parameter space in an inert doublet model with two active doublets
Standard Model Fermion Hierarchies with Multiple Higgs Doublets
Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets
C–H Arylation with Platinum
Constraints on the parameter space in an inert doublet model with two active doublets
Standard Model Fermion Hierarchies with Multiple Higgs Doublets
Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets
C–H Arylation with Platinum
Constraints on the parameter space in an inert doublet model with two active doublets
Standard Model Fermion Hierarchies with Multiple Higgs Doublets
Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy